Indy Precision Oncology Symposium

Indy Hematology Education is a nonprofit educational organization that focuses on educating providers on malignant conditions to increase knowledge, enhance awareness, and, ultimately, improve outcomes for patients with malignant conditions. Rare diseases frequently treated in the community can pose a major challenge to treating physicians, advanced practitioners, and nurses. Additionally, there is sometimes a lack of consensus criteria for the management of these disorders. The rarity of the disease states further exacerbates these issues; therefore, there are infrequent presentations to treating physicians who have difficulty establishing significant expertise in treating these rare conditions. However, despite the rarity of these diseases, most patients are treated in the community. Thus, the education of providers in community practice is imperative and warranted in order to promote a better understanding of the diagnosis, treatment, and emerging therapeutics for the management of these disorders.

Given the above, Indy Hematology Education is hosting the Annual Precision Oncology Symposium in Indianapolis on August 29th, 2026. This meeting will result in an invitation of leading physicians from across the globe and the United States to present current and emerging practice products and diagnostic strategies for these rare disorders. We intend to cover pathology and the interpretation of NGS studies in the treatment of acute leukemias, mastocytosis, and lymphomas. We will provide practical strategies and a tool kit for the management of acute leukemias in community practice, including patients with driver mutations, those who are ineligible for intensive chemotherapy, and the treatment of acute lymphoblastic leukemia. We will cover the treatment of the exceedingly rare condition of Blastic Plasmacytoid Dendritic Cell Neoplasm. This rare leukemia is usually associated with fatality, and an understanding of emerging treatment and diagnostic strategies, as well as other management options, will be discussed. Other diseases to be addressed would include T-cell lymphomas and leukemias and hematologic conditions, including Cold Agglutinin Disease, Thrombotic Thrombocytopenic Purpura, Paroxysmal Nocturnal Hemoglobinemia, Hemophagocytic Lymphocytosis, and Porphyrias, as well as Systemic Mastocytosis. In addition, the treatment of rare plasma cell dyscrasias, monoclonal gammopathy of renal significance, POEMS syndrome, and amyloidosis will be addressed. Emerging options for the treatment of patients with neoplastic disorders with driver mutations has become an increasing challenge for treating providers. Therefore, we will address and discuss molecular pathology and diagnostics of neoplastic conditions including, but not limited to, lung cancer, and the utility of targeted and driver mutational targeted therapy in the treatment of lung cancer as well as immunotherapy including bispecific antibody therapy in the treatment of nonsmall cell and small cell lung cancer.

Furthermore, approaches to the management of cancer in a tumor agnostic manner with targeted therapies will be thoroughly reviewed and discussed. We believe at the end of this symposium, attending providers will be better equipped in their understanding of these rare disorders and in the treatment of patients presenting to their practices yielding an improvement of treatment and therapeutic outcomes. We invite all to support this important endeavor, and we hope that your support will continue to enhance the outcomes of patients treated within our practice.

Additionally, support for these programs and equipping practitioners and providers in the management of these disorders in the community would help improve disparities in treatment outcomes, which are common in the treatment of rare malignancies in the United States and globally.